Stick With Traditional Opioid Formulations for Most Patients

The Zohydro controversy will lead to more interest in "abuse-deterrent" opioid formulations.

Zohydro is the new long-acting hydrocodone for chronic, severe pain. It's controversial because it's NOT an abuse-deterrent formulation...despite concerns about its abuse potential.

Abuse-deterrent formulations aren't required by FDA...but are being promoted in an effort to reduce prescription opioid abuse.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote